Dr Peters current work is focused on use of different antihypertensives, frailty and risk and benefit of treatment in the very elderly.
Between 2010 and 2012 Dr Peters was part of the core team setting up and developing the Imperial Clinical Trials Unit (ICTU). ICTU was launched in 2010 and is a fully UKCRC registered trials unit.
Prior to 2010 she led the multinational HYpertension in the Very Elderly Trial Cognitve function (HYVET-COG) study and co-ordinated the main Hypertension in the Very Elderly [HYVET] trial. HYVET was an Imperial sponsored multinational double blind RCT which was rated ‘Trial of the year’ by the Society for Clinical Trials and an exceptional landmark in medicine(F1000) in 2008. The HYVET trial results have changed global guidelines for the use of antihypertensive treatment in older adults (>=80 years).
Research interests include risk factors for dementia, particularly cardiovascular risk factors and potential interventions to ameliorate or prevent cognitive decline and dementia.
et al., 2017, Joining forces to prevent dementia: The International Research Network On Dementia Prevention (IRNDP)., Int Psychogeriatr, Pages:1-4
et al., 2017, Antihypertensive treatment decreases arterial stiffness at night but not during the day. Results from the Hypertension in the Very Elderly Trial, Blood Pressure, Vol:26, ISSN:0803-7051, Pages:109-114
et al., 2016, Left ventricular hypertrophy is a predictor of cardiovascular events in elderly hypertensive patients: Hypertension in the Very Elderly Trial, Journal of Hypertension, Vol:34, ISSN:0263-6352, Pages:2280-2286
et al., 2016, Type 2 Diabetes as a Risk Factor for Dementia in Women Compared With Men: A Pooled Analysis of 2.3 Million People Comprising More Than 100,000 Cases of Dementia, Diabetes Care, Vol:39, ISSN:0149-5992, Pages:300-307
et al., 2016, Literature review of visual representation of the results of benefit-risk assessments of medicinal products, Pharmacoepidemiology and Drug Safety, Vol:25, ISSN:1053-8569, Pages:238-250